Skip to main content
Top
Published in: Gut Pathogens 1/2021

Open Access 01-12-2021 | Ciprofloxacin | Research

Characteristics of patients infected with Clostridioides difficile at a Saudi Tertiary Academic Medical Center and assessment of antibiotic duration

Authors: Khadijah M. Alammari, Abrar K. Thabit

Published in: Gut Pathogens | Issue 1/2021

Login to get access

Abstract

Background

Clostridioides difficile infection (CDI) is a common hospital-associated diarrhea. Several antibiotics commonly associate with CDI; however, limited data are available on the duration of exposure prior to CDI. Moreover, studies on the characteristics of CDI patients in Saudi Arabia are limited. Therefore, this study aimed to characterize CDI patients identified over 10 years and assess antibiotic days of therapy (DOT) prior to CDI.

Methods

This was a retrospective descriptive analysis of CDI patients at a Saudi tertiary academic medical center between December 2007 and January 2018. Patients characteristics, prior exposure to known CDI risk factors, and DOT of antibiotics prior to CDI incidence were assessed.

Results

A total of 159 patients were included. Median age was 62 years. Most cases were hospital-acquired (71.1%), non-severe (44.7%), and admitted to medical wards (81.1%). Prior exposure to antibiotics and acid suppression therapy were reported with the majority (76.1 and 75.5%, respectively). The most frequently prescribed antibiotics were piperacillin/tazobactam, ceftriaxone, meropenem, and ciprofloxacin with median DOTs prior to CDI incidence of 14 days for the β-lactams and 26 days for ciprofloxacin. The distribution of DOT was significantly different for piperacillin/tazobactam in different units (P = 0.003) where its median DOT was the shortest in medical wards (11 days), and for ciprofloxacin among different severity groups (P = 0.013), where its median DOT was the shortest in severe CDI patients (11 days).

Conclusion

Most patients in this study had hospital-acquired non-severe CDI and were largely exposed to antibiotics and acid suppression therapy. Therefore, such therapies should be revised for necessity.
Literature
1.
go back to reference McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–94. https://doi.org/10.1093/cid/ciy149.CrossRefPubMed McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–94. https://​doi.​org/​10.​1093/​cid/​ciy149.CrossRefPubMed
11.
go back to reference Malekzadegan Y, Halaji M, Hasannejad-Bibalan M, Jalalifar S, Fathi J, Ebrahim-Saraie HS. Burden of Clostridium (Clostridioides) difficile infection among patients in Western Asia: a systematic review and meta-analysis. Iran J Public Health. 2019;48(9):1589–99.PubMedPubMedCentral Malekzadegan Y, Halaji M, Hasannejad-Bibalan M, Jalalifar S, Fathi J, Ebrahim-Saraie HS. Burden of Clostridium (Clostridioides) difficile infection among patients in Western Asia: a systematic review and meta-analysis. Iran J Public Health. 2019;48(9):1589–99.PubMedPubMedCentral
17.
go back to reference Biosynex Group. IMMUNOQUICK®: Clostridium difficile GDH and Tox A/B product catalog. Strasbourg Cedex, France. 2015. Biosynex Group. IMMUNOQUICK®: Clostridium difficile GDH and Tox A/B product catalog. Strasbourg Cedex, France. 2015.
18.
go back to reference Centers for Disease Control and Prevention. Antimicrobial Use and Resistance (AUR) Module. Atlanta, GA. 2020. Centers for Disease Control and Prevention. Antimicrobial Use and Resistance (AUR) Module. Atlanta, GA. 2020.
25.
go back to reference Blot E, Escande MC, Besson D, Barbut F, Granpeix C, Asselain B, et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect. 2003;53(3):187–92.CrossRef Blot E, Escande MC, Besson D, Barbut F, Granpeix C, Asselain B, et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect. 2003;53(3):187–92.CrossRef
Metadata
Title
Characteristics of patients infected with Clostridioides difficile at a Saudi Tertiary Academic Medical Center and assessment of antibiotic duration
Authors
Khadijah M. Alammari
Abrar K. Thabit
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2021
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-021-00405-9

Other articles of this Issue 1/2021

Gut Pathogens 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.